Despite a growing backlog and impressive revenue growth, Nvidia stock (NASDAQ: NVDA) is not immune to market-wide pullbacks. NVDA shares entered a prolonged period of range-bound trading in October of 2024, when the $140 mark was first breached, albeit briefly. The stock traded between $130 and $140 without a clear trend present until an all- time high (ATH) of $149.43 was reached on January 6. This did not signal the start of an uptrend, however — in late January, the sudden emergence of DeepSeek as a wort ...

United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty. Notably, the market is already on the downside, as Trump recently announced an additional 25% tariff on auto imports. It remains to be seen how a similar move in pharmaceuticals will evolve. Although the initial reaction to tariffs has led to ...

United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty. Notably, the market is already on the downside, as Trump recently announced an additional 25% tariff on auto imports. It remains to be seen how a similar move in pharmaceuticals will evolve. Although the initial reaction to tariffs has led to ...

Core Viewpoint - Michael Burry's top holding, Alibaba, has received a significant price target increase from Wall Street, driven by its potential in artificial intelligence [1][5][6] Group 1: Stock Performance - Alibaba's stock has experienced increased volatility, closing at $132.43 on March 28, down 2.36%, but remains one of the best-performing stocks year-to-date with over 55% gains [2] - The stock broke key levels around $104.40 and $109.10, leading to gains of over 20%, and is currently consolidating within a strong uptrend [5] Group 2: Analyst Upgrades - Mizuho Securities raised its price target for Alibaba from $140 to $170, a 20% increase, maintaining an 'Outperform' rating and naming it a top pick in the Asia internet sector [5][10] - Citi and Benchmark also maintain bullish ratings with price targets of $170 and $190 respectively, citing Alibaba's advancements in AI and growth in e-commerce and cloud computing [10][11] Group 3: AI and Growth Potential - Mizuho's analyst highlighted Alibaba's strong positioning in the AI landscape as a key driver for the upgrade, particularly after the announcement of its new AI model, QwQ-32B [6][7] - The company is expected to scale AI models toward artificial general intelligence (AGI) and provide end-user solutions across various industries, which are seen as bullish catalysts [7][8] Group 4: Financial Outlook - Mizuho increased its fiscal year 2026 cloud revenue growth forecast from 13% to 17% year-over-year, reflecting a stronger product roadmap and improving sentiment around enterprise IT spending in China [9] - Alibaba's fundamentals are strong, with expectations of double-digit growth in e-commerce as retail sales recover in the Chinese economy [12] Group 5: Corporate Stability - Investor confidence is returning as Alibaba's leadership has solidified its corporate strategy, reversing previous plans to spin off key businesses, which enhances long-term optimism [13]

Core Viewpoint - The divergence in stock performance between Eli Lilly and Novo Nordisk since the start of 2025 highlights the impact of product pipelines and market perceptions in the biotech sector, with Eli Lilly showing a YTD increase of 6.97% while Novo Nordisk has seen a decline of 18.87% [1][2]. Company Performance - Eli Lilly's stock is currently trading at a forward price-to-earnings (PE) ratio of 36.26, while Novo Nordisk's forward PE is significantly lower at 17.23, indicating a more attractive valuation for Novo Nordisk [4]. - The trailing PE ratios for Eli Lilly and Novo Nordisk are 69.29 and 21.45, respectively, further emphasizing the valuation gap [4]. Market Outlook - Analysts from Bank of America have expressed concerns about Novo Nordisk potentially missing first-quarter sales expectations, which could lead to a 2% reduction in full-year sales guidance, projecting a sales growth range of 14% to 22% for the year [6]. - Despite the concerns, Bank of America maintains that Novo Nordisk's guidance remains competitive against Eli Lilly, with a revised price target of $131, down from $155, still suggesting an upside of 87% to 70% [7]. Analyst Sentiment - Currently, 10 analysts are tracking Novo Nordisk, with an equal split of five ratings as 'Buy' and five as 'Hold'. The average price target is $110.36, indicating a potential upside of 58.13% from current prices [8][11]. - Novo Nordisk is noted as one of the stocks with the largest projected upside according to Wall Street analysts [8].

Core Viewpoint - Nvidia's stock has faced significant volatility in 2025, with a general downward trend since the beginning of the year, threatening to drop below $100 again [1]. Insider Trading Activity - Nvidia insiders have been actively selling shares, with nearly $20 million worth of stock sold since March began [2]. - Notable insider trades include Colette Kress, who sold 66,660 shares for approximately $7.8 million at an average price of $116.83 on March 21 [5]. - Director Robert Burgess sold 53,324 shares for $6.16 million at an average price of $115.49 on March 13, while Director Aarti Shah sold 20,000 shares for $2.37 million at $118.42 on March 20 [6]. - Smaller trades were executed by Principal Accounting Officer Donald Robertson ($525,585) and Director John Dabiri ($292,930) [7]. Stock Performance and Market Sentiment - Despite the insider selling, all trades in 2025 were executed above Nvidia's stock price of $111.98 at the time of reporting [9]. - Nvidia's stock is down 16.61% year-to-date, influenced by various headwinds including regulatory concerns, increased competition from China, internal production issues, recession fears, and warnings about a potential bubble in the data center market [11].

Core Viewpoint - Nio's stock experienced a significant decline following a disappointing quarterly earnings report, despite earlier gains due to subsidy announcements. The company's outlook remains uncertain amid increased short selling and potential share dilution from a new offering [1][2][9]. Financial Performance - Nio's Q4 and FY earnings report revealed an earnings per share (EPS) miss and revenues below expectations, leading to weaker guidance [1]. - The stock price dropped to $3.93 by March 27, representing a 24.71% decrease from its YTD high of $5.22 [2]. Analyst Sentiment - Despite recent setbacks, Wall Street analysts maintain a consensus 'hold' rating on Nio, with an average 12-month price forecast suggesting a potential upside of 16.35% [3]. - There is a noted disconnect between analyst coverage and market actions, as the short volume ratio for Nio shares increased sharply post-earnings report, indicating heightened bearish sentiment [4]. Market Activity - The short volume ratio rose from 41.18 on March 21 to 67.71 by March 27, reflecting increased bearish interest among investors [4]. - A recent announcement indicated that Nio plans to offer up to 118.8 million shares outside the U.S., which could lead to approximately 5.77% dilution of existing shares [9][10]. Growth Prospects - Nio has shown year-over-year growth in vehicle deliveries, but this has not translated into improved financial performance, raising concerns amid unstable macro conditions and weak guidance [7]. - The proceeds from the new share offering are intended for research and development, which could serve as a growth catalyst if managed effectively, although benefits may take time to materialize [10][11].

Group 1 - AMD stock has been on a downward trajectory in 2025, with concerns that it could fall below $100, which it did by the end of February [1] - As of March 26, AMD stock was trading at $109.68, recovering from previous losses and reducing year-to-date losses to 9.20% [2] - Investment strategist Shay Boloor suggested that now might be the right time to invest in AMD, citing historical rebounds when the stock pulled back to a forward price-to-earnings (PE) ratio of 20 [3][4] Group 2 - The stock is considered affordable at its current low forward PE compared to peers, but questions remain about its bullish potential [5] - Wall Street analysts have a bullish outlook, with an average 12-month price forecast of $147.88, indicating a potential upside of 34.82% from current prices [6] - Despite the potential for an uptick, there is no guarantee that the rebound will be significant or long-lasting, as seen in past trends [7] Group 3 - Reasons to be bullish on AMD include strong core operations and unexpectedly high demand for its latest GPUs, although it may not capture a significant share of the AI market from Nvidia [8]

Core Viewpoint - The U.S. stock market has experienced volatility with a bearish trend, particularly affecting the Magnificent 7 technology companies, including Nvidia, which has seen significant stock price drops recently [1][3]. Group 1: Nvidia's Stock Performance - Nvidia shares have become a major concern, experiencing a significant drop of 5.58% on March 26, trading at $113.96 [2][3]. - There are fears that Nvidia's stock may fall below $100, which would mark a significant decline from its historical performance [5]. - The company's market capitalization has reached trillions, indicating its influence on other major stocks [2]. Group 2: External Pressures and Market Conditions - The technology sector is facing challenges due to the ongoing trade war initiated by President Donald Trump, which has heightened recessionary fears [7]. - Concerns about a potential bubble in global data center infrastructure, a key revenue source for Nvidia, have been raised by industry leaders [8]. - New environmental regulations in China may restrict Nvidia's ability to sell some of its most profitable chips, further impacting its market position [9].

The biggest thing Tesla (NASDAQ: TSLA) stock gave to its investors in the last 30 days of trading has been an emotional rollercoaster. First, TSLA shares dropped nearly 25% between late February and March 10, only to enter a period of volatility and, in the most recent sessions, to rally nearly 28% in a week.Still, Tesla stock’s press time price of $288.14 means that it remains 12.82% down in the last 30 days, while short volume ratio data, retrieved by Finbold from Fintel on March 26, indicates few are con ...